Bruce C Cree

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Neuromyelitis optica: diagnosis, pathogenesis, and treatment
    Bruce Cree
    Multiple Sclerosis Center, University of California San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Curr Neurol Neurosci Rep 8:427-33. 2008
  2. ncbi Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, USA
    Arch Neurol 66:226-33. 2009
  3. ncbi A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e11296. 2010
  4. ncbi Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    Bruce A C Cree
    Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
    Ann Neurol 68:145-50. 2010
  5. ncbi Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data
    Bruce A C Cree
    UCSF Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, 94117, USA
    Arch Neurol 68:464-8. 2011
  6. ncbi Emerging monoclonal antibody therapies for multiple sclerosis
    Bruce Cree
    Multiple Sclerosis Center at UCSF, San Francisco, California 94117, USA
    Neurologist 12:171-8. 2006
  7. ncbi Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis
    Til Menge
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143-0114, USA
    J Allergy Clin Immunol 116:453-9. 2005
  8. ncbi Risk alleles for multiple sclerosis identified by a genomewide study
    David A Hafler
    Division of Molecular Immunology, Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, and Harvard Medical School, Boston, USA
    N Engl J Med 357:851-62. 2007
  9. ncbi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009

Research Grants

  1. Correlating Multiple Sclerosis Phenotypes with Genotypes
    Bruce Cree; Fiscal Year: 2007

Detail Information

Publications9

  1. ncbi Neuromyelitis optica: diagnosis, pathogenesis, and treatment
    Bruce Cree
    Multiple Sclerosis Center, University of California San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Curr Neurol Neurosci Rep 8:427-33. 2008
    ..This review discusses the discovery of the NMO-IgG biomarker, the identification of AQP4 as its target, the clinical applications of these advances, the pathologic implications for the anti-AQP4 antibody, and advances in NMO treatment...
  2. ncbi Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, USA
    Arch Neurol 66:226-33. 2009
    ....
  3. ncbi A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e11296. 2010
    ..Whether other major histocompatibility complex (MHC) genes contribute to MS susceptibility is controversial...
  4. ncbi Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    Bruce A C Cree
    Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
    Ann Neurol 68:145-50. 2010
    ..To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients...
  5. ncbi Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data
    Bruce A C Cree
    UCSF Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, 94117, USA
    Arch Neurol 68:464-8. 2011
    ..Because patients of African descent may be less responsive to interferon beta treatment than patients of white race/ethnicity, the efficacy of natalizumab therapy in this population is clinically important...
  6. ncbi Emerging monoclonal antibody therapies for multiple sclerosis
    Bruce Cree
    Multiple Sclerosis Center at UCSF, San Francisco, California 94117, USA
    Neurologist 12:171-8. 2006
    ..Because of their accessibility, proteins expressed on the surface of immune system cell lineages are appealing targets for monoclonal antibody therapies...
  7. ncbi Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis
    Til Menge
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143-0114, USA
    J Allergy Clin Immunol 116:453-9. 2005
    ..This novel assay is a suitable and valuable method to increase accuracy of diagnosis and disease staging in MS...
  8. ncbi Risk alleles for multiple sclerosis identified by a genomewide study
    David A Hafler
    Division of Molecular Immunology, Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, and Harvard Medical School, Boston, USA
    N Engl J Med 357:851-62. 2007
    ..Multiple sclerosis has a clinically significant heritable component. We conducted a genomewide association study to identify alleles associated with the risk of multiple sclerosis...
  9. ncbi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...

Research Grants2

  1. Correlating Multiple Sclerosis Phenotypes with Genotypes
    Bruce Cree; Fiscal Year: 2007
    ....